The Management of Atopic Dermatitis: Entering a New Paradigm Web Activity
| EXPERT FACULTY | ||||||||||||
|
||||||||||||
 |
||||||||||||
TARGET AUDIENCE
STATEMENT OF NEED/PROGRAM OVERVIEW
Atopic dermatitis (AD), or eczema, is a complex, chronic, relapsing inflammatory skin disease marked by pruritus and skin irritation. Recent studies have documented the adverse effects of AD on mental health and quality of life and new evidence suggests a relationship between AD and other chronic, nonallergic conditions including obesity, cardiovascular disease, autoimmunity, and malignancies. This activity is focused on AD diagnosis and treatment, impact of emerging therapies, adherence to therapy, and management of the pharmacy benefit. It is specifically designed to meet the needs of health care decision makers (HCDMs) from health plans, insurers, health systems, and other payers responsible for the benefit management, therapeutic category review, and AD clinical pathway development.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
CHAPTER 1
CHAPTER 2
ACCREDITATION
Joint Accreditation Statement
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.
Interprofessional Continuing Education
 |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
|
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
| Name of Faculty or Presenter | Reported Financial Relationship |
| Jeffrey Dunn, PharmD, MBA | No financial interest/relationships relating to the topic of this activity |
| Paul Yamauchi, MD, PhD | Consulting fees (ex. advisory boards) – Novartis Pharmaceuticals Corporation, Lilly USA, LLC, Amgen, Inc., AbbVie, Inc., Janssen Pharmaceuticals, Valeant Pharmaceuticals |
| Edmund Pezalla, MD, MPH | No financial interest/relationships relating to the topic of this activity |
The PIM planners and managers have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of September 18, 2018 through March 31, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.
MEDIA
Internet
FEE INFORMATION
There is no fee for this educational activity.
